Single-Dose CIDEB siRNA Cuts Liver Fat Up to 80% in MASLD, Published in NEJM
REGN sits 52% above its 52-week low of $591.52.
Summary
A single subcutaneous dose of Regeneron's first-in-class CIDEB siRNA cut liver fat by 58-80% at week 36 in a Phase 1/2 MASLD trial, with 62% of treated patients normalizing liver fat versus none on placebo. The data were simultaneously published in the New England Journal of Medicine and presented orally at AASLD, a strong validation signal for a program Regeneron built from its own genetics center discovery. Depth of fat reduction beats the 47-57% at roughly one year reported for currently approved MASH therapies, and the clean tolerability profile with no nausea or vomiting addresses a key limitation of rivals. This is early-stage — Phase 2a, 2b and Phase 3 trials are only now recruiting — so revenue is years away, but it materially strengthens the cardiometabolic pipeline story alongside the recent Sanofi immunology expansion. Regeneron hosts a virtual roundtable on its MASH programs November 10 at 8:30 a.m. ET.
At the time of this announcement, REGN was trading at $900.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.5B. The 52-week trading range was $591.52 to $991.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.